These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20864811)

  • 21. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
    Brockhoff G; Heckel B; Schmidt-Bruecken E; Plander M; Hofstaedter F; Vollmann A; Diermeier S
    Cell Prolif; 2007 Aug; 40(4):488-507. PubMed ID: 17635517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
    Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
    BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
    Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.
    Hoffmann S; Burchert A; Wunderlich A; Wang Y; Lingelbach S; Hofbauer LC; Rothmund M; Zielke A
    Endocrine; 2007 Apr; 31(2):105-13. PubMed ID: 17873319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in malignant peripheral nerve sheath tumor cells.
    Kohli L; Kaza N; Lavalley NJ; Turner KL; Byer S; Carroll SL; Roth KA
    Neuro Oncol; 2012 Mar; 14(3):266-77. PubMed ID: 22259051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pentagalloylglucose induces autophagy and caspase-independent programmed deaths in human PC-3 and mouse TRAMP-C2 prostate cancer cells.
    Hu H; Chai Y; Wang L; Zhang J; Lee HJ; Kim SH; Lü J
    Mol Cancer Ther; 2009 Oct; 8(10):2833-43. PubMed ID: 19825802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
    Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
    Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer.
    Zulkifli A; Tan FH; Areeb Z; Stuart SF; Gomez J; Paradiso L; Luwor RB
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
    Jhawer M; Goel S; Wilson AJ; Montagna C; Ling YH; Byun DS; Nasser S; Arango D; Shin J; Klampfer L; Augenlicht LH; Perez-Soler R; Mariadason JM
    Cancer Res; 2008 Mar; 68(6):1953-61. PubMed ID: 18339877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III.
    Xu W; Song F; Wang B; Li K; Tian M; Yu M; Pan X; Shi B; Liu J; Gu J; Li Z; Jiang H
    Cell Physiol Biochem; 2018; 46(1):226-237. PubMed ID: 29587298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells.
    Meira DD; de Almeida VH; Mororó JS; Nóbrega I; Bardella L; Silva RL; Albano RM; Ferreira CG
    Br J Cancer; 2009 Sep; 101(5):782-91. PubMed ID: 19654571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
    Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
    Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of autophagy enhances apoptotic cell death via epidermal growth factor receptor inhibition by canertinib in cervical cancer cells.
    Aydinlik S; Dere E; Ulukaya E
    Biochim Biophys Acta Gen Subj; 2019 May; 1863(5):903-916. PubMed ID: 30825616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
    Lu Y; Liang K; Li X; Fan Z
    Mol Cancer; 2007 Oct; 6():63. PubMed ID: 17931419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
    Rebucci M; Peixoto P; Dewitte A; Wattez N; De Nuncques MA; Rezvoy N; Vautravers-Dewas C; Buisine MP; Guerin E; Peyrat JP; Lartigau E; Lansiaux A
    Int J Oncol; 2011 Jan; 38(1):189-200. PubMed ID: 21109940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.